UNSPSC 51111626: Bexarotene

This classification denotes a retinoic acid agent with the molecular formula C24H28O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A61RXM4375, chemically known as 4-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid but generally known as bexarotene, which bears US NIH Compound Identifier 82146. European Medicines Agency schedules Bexarotene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00795MIG.

UNSPSC 51111626 Bexarotene, a Commodity code, covers pharmaceutical products procured by state and local health agencies—in this case, prescription medications and related pharmacy benefit management services. State and local governments buy under this code primarily through health and human services departments managing pharmacy benefit programs for state employees, retirees, and Medicaid beneficiaries. The scope of work includes direct pharmaceutical procurement, pharmacy benefit administration, and emerging direct-to-manufacturer prescription fulfillment models that bypass traditional pharmacy benefit managers and group purchasing organizations. Issuing bodies are predominantly state health and human services commissions and related state agency pharmacy programs.

The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program—an exploratory procurement mechanism designed to gather market intelligence before formal solicitation. The RFI targets vendors with direct contracting experience for self-insured employers and health plans in both private and government sectors, flexibility in negotiated net pricing models, and capability to implement value-based or outcomes-based agreements. No award value, budget range, or formal response deadline binding on the state was identified in the RFI materials; the state characterized this phase as foundational research to inform future RFP development and procurement strategy rather than a competitive solicitation with established financial or temporal parameters. Geographic activity is currently concentrated in Texas; no other state or local opportunities appear in the recent record.